Separation type: Bridge Ion Separation Technology, or BIST™ by SIELC Technologies
High Performance Liquid Chromatography (HPLC) Method for Analyses of Bivalirudin and Asp9 – bivalirudin
Bivalirudin is a short, 21-amino-acid peptide. It has 2 basic and 6 acidic groups. It is a naturally-occurring anticoagulant. Asp9-bivalirudin is a process impurity and can be a result of the degradation of the drug bivalirudin. SIELC’s new BIST™ mode can retain and separate Bivalirudin and its degredant with a TMDAP phosphate buffer, and the respective retention times can be controlled by altering the pH of the buffer.
Condition
| Column | BIST™ A+, 2.1×100 mm, 3µm, 100A |
| Mobile Phase | MeCN – 30% |
| Buffer | TMDAP phosphate – 5 mM pH 5.0, pH 6.0 |
| Flow Rate | 0.2 mL/min |
| Detection | UV 275 nm |
Description
| Class of Compounds | Drugs, Anticoagulant |
| Analyzing Compounds | Bivalirudin and Asp9 – bivalirudin |
Application Column
BIST A+
BIST™ columns offer a unique and effective way to achieve separations that were traditionally challenging or even impossible with other HPLC columns. With the use of a special mobile phase, these ion exchange columns provide very strong retention for analytes with the same charge polarity as the stationary phase, unlocking new chromatography applications. What makes BIST™ columns stand out is their proprietary surface chemistry, which results in superior selectivity, resolution, and sensitivity. These columns offer a simple, efficient solution for a variety of analytical challenges, making them an excellent choice for researchers and analysts across many different fields. To learn more about the technology that powers BIST™ columns and to explore related applications, check out https://BIST.LC.
Select options
